9 June 2021
Blueberry Therapeutics secures further investment
NPIF – Maven Equity Finance, managed by Maven Capital Partners (“Maven”) and part of the Northern Powerhouse Investment Fund (“NPIF”) has invested £750,000 in Blueberry Therapeutics Limited (“Blueberry”), a drug discovery and...
26 May 2021
Infex Therapeutics partners with Alderley Analytical
Alderley Park, Cheshire Infex Therapeutics has today announced a deal with Alderley Analytical, to support PK and ADA analysis of Infex’s RESP-X program. RESP-X is an anti-virulence therapy in-licensed from Japanese pharma company Shionogi. It is designed to help the body...
17 May 2021
INFEX Therapeutics appoints Lonza to manufacture new lung infection drug
Alderley Park, Cheshire - Infex Therapeutics has awarded a £1m contract to Lonza to help progress its RESP-X program, a novel therapy which targets serious recurrent respiratory infections in patients with damaged lung functions. RESP-X is expected to enter clinical trials...
10 May 2021
Digital health start-up Clin-e-cal launches free app to help improve inhaler technique and reduce asthma attacks
Manchester-based digital health start-up Clin-e-cal has launched a free app to help people with respiratory diseases to monitor and improve their inhaler technique. The Clip-Tone Buddy app is the first digital solution which can provide real time feedback and effectively guide a...
4 May 2021
British Pharmaceutical Company Maxwellia Secures Government Future Fund investment to Spearhead Shift in Self-Care
Maxwellia, a pioneering British business that is poised to transform the UK’s self-care market through its specialist model of making more medicines available to buy from UK pharmacies has received a £500k investment from the UK Government via conversion of its...
29 April 2021
Viscgo secures investment to launch its innovative device to improve quality of life for people with swallowing difficulties
MANCHESTER, UK: 28th April 2021 -Viscgo Limited, a ground-breaking new medical device company, today announced receipt of £265,000 investment to launch its first-generation device to improve the management of dysphagia (swallowing difficulties). The funding came from a...
29 April 2021
Panthera becomes the world’s first clinical trial site to administer Valneva’s inactivated COVID-19 vaccine (VLA2001) to volunteers in phase 3 study
Panthera has today, (28thApril 2021) started vaccinating volunteers in Valneva’s double-blind, phase three, COVID prevention trial. The trial will compare Valneva’s inactivated vaccine, VLA2001, with AstraZeneca’s conditionally approved vaccine Vaxzeria. Unlike...
13 April 2021
Maxwellia on course to launch self-care alternatives following £3.2m funding round
A Cheshire business that aims to transform the UK’s self-care market has secured a £3.2m investment in a funding round led by Manchester-based Praetura Ventures. Maxwellia, which is based at Alderley Park, aims to give people easier and faster access to the...
12 April 2021
Deals agreed as Infex's resistance bypass drug program heads for clinic
Alderley Park, Cheshire Infex Therapeutics has appointed Pharmaron to help progress its MET-X program which targets urinary tract infections caused by WHO critical-priority resistant Gram-negative bacteria. Pharmaron will manufacture the patented molecule at its plant in...
7 April 2021
Panthera Biopartners appoints corporate financier Christopher Steed as a non-executive director to continue UK and overseas expansion
Independent clinical trial site management organisation (SMO), Panthera Biopartners, has appointed M&A and fundraisings adviser Chris Steed as a non-executive director. Chris has over 25 years’ experience as a corporate financier, working at Arthur Andersen, Deloitte...